Effect of macrophage activation on niosome encapsulated bleomycin in tumor bearing mice

Indian Journal of Pharmacology

Volumn 28, Issue 3, 1996, Pages 175-180

  Raja Naresh, R A ^a   Udupa, N ^a   Uma Devi, P ^a  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

macrophage activation; muramyl dipeptide; niosomal bleomycin; tuftsin; tumor

Indexed keywords

BLEOMYCIN; CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; IMMUNOMODULATING AGENT; LIPID; MURAMYL DIPEPTIDE; NIOSOME; SORBITAN STEARATE; TUFTSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DRUG TARGETING; EHRLICH ASCITES TUMOR; ENCAPSULATION; HEAT SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; SARCOMA 180; SURVIVAL TIME; TECHNIQUE;

EID: 0029797042     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Handjani Vila RM, Ribier A, Rondot B, Vanlerberghe G. Dispersion of lamellar phases of non ionic lipids in cosmetic products. Int J Cos Sci 1979;1:303-14.
2. Baillie AJ, Florence AT, Florence AT, Hume LR, Muirhead GT, Rogerson A. The effects of cholesterol on single chain, non ionic surfactant vesicles. J Pharm Pharmacol (Suppl.) 1984;36:48.
3. Azmin MN, Florence AT, Handjani Vila RM, Stwart JF, Vanlerberghe G, Whittaker JS The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 1985;37:237-42.
4. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes nonionic surfactant vesicles. J Pharm Pharmacol 1985;38.863-8.
5. Rogerson A, Cummings J, Willmott N, Florence AT. The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol 1988;40:337-43.
6. Baillie AJ, Coombs GH, Dolan TF, Laune J. Non ionic surfactant vesicles, niosomes as a delivery system for the anti-leishmanial drug sodium stibogluconate. J Pharm Pharmacol 1986;38:502-5.
7. Fidler IJ, Barnes Z, Fogler WE, Kirsch R, Bugelski P, Poste G. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activatior. Cancer Res 1982;42:496-501.
8. Shlome D, Philio G, Esther T et al. Tuftsin analogues: synthesis, structure function relationships and implication for specificity of Tuftain's bioactivity. J Med Chem 1986;29:1961-8.
9. Whitworth WP, Charles CP, Joseph E, Eugenis SK, Fidler IJ. Macrophages and Cancer, Cancer Metasta. 1990;8: 319-51.
10. Gregoriadis G, Neerunjun ED, Hunt R. Fate of a liposome associated agent injected into normal and tumor bearing rodents. Attemps to improve localisation in tumor tissues. Life Sci 1977; 21:357-70.
11. Sefton MV, Horvath V, Allen DG, Zingg W. Insulin delivery from an implanted controlled release micro pump in pancreaticemised dogs. Trans Soc Artif Intern Organs 1983;714-9.
12. Poste G, Kirsh R, Fogler WS, Fidler IJ. Liposomes as a drug delivery system in cancer therapy. Novel approach to cancer chematherapy. Orlands FL: Academic Press, 1984:166-231.
13. Fidler IJ, Sone S, Fogler WE, Barnes Z. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 1981;78:1680.
14. Fichtner I, Arndit D, Reszka R, Gens J. Pharmacokinetic behaviour of (57 Co) bleomycin liposomes in mice. Comparison with the encapsulated substance Anticancer Drugs 1995;1:555-63.
15. Fielding RM. Liposomal drug delivery. Clin Pharmacokinet 1991;1:155-64.
16. Gregoriadis G. The liposome drug carrier concept, its development and future. In: Gregoriadis G, Allison A, (eds). Liposomes in Biological systems. London: Academic Press, 1980:45-50.
17. Mathews DE, Farewell V. Kaplan Meir Acturial Survival curves. In: Using and understanding medical statistics Karger, Basel. 1985:67-78.